Harris Erik 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
Harris Erik
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
2024-03-01+19,400→ 70,681 total - Award
Common Stock
2024-03-01+957→ 71,638 total - Sale
Common Stock
2024-03-01$53.76/sh−4,768$256,328→ 67,163 total - Award
Stock Option (Right to Buy)
2024-03-01+34,200→ 34,200 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (34,200 underlying)
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]Includes 293 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on October 31, 2023.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.